Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in cardiometabolic risk factors.
|Slideshows|February 15, 2019
Early Menopause Linked to Shorter Life and Diabetes
Author(s)Gregory M. Weiss, MD
Researchers found that women who experience early menopause do not live as long and experience more years with type 2 diabetes mellitus.
Advertisement
Advertisement
Related to this article
TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data.
TMS 2026: Only 21.7% of women initiated menopause hormone therapy, with significant racial disparities and low treatment persistence, a new study finds.
TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.
JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.
TMS 2026: Women exercising at least 5 days a week reported lower perimenopause symptom scores across psychological, somatic, and urogenital domains.
TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women
TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.
Advertisement
Advertisement
Trending on Patient Care Online
1
What the CLARITY Study Means for Counseling on Long-Acting HIV PrEP
2
CagriSema Cuts Weight Up to 27% Across Menopause Stages: TMS 2026
3
Implementing Long-Acting HIV PrEP: Clinic and Pharmacy Infrastructure
4
3 Questions Primary Care Physicians Should Ask About Menopause Symptoms, With Stephanie Faubion, MD
5